Skip to main content
Erschienen in: Inflammation 3/2023

15.03.2023 | ORIGINAL ARTICLE

Inhibition of Cdc37 Ameliorates Arthritis in Collagen-Induced Arthritis Rats by Inhibiting Synoviocyte Proliferation and Migration Through the ERK Pathway

verfasst von: Weiwei Sun, Xingxing Mao, Weijie Wu, Yunyi Nan, Chunxiang Xu, Youhua Wang, Hua Xu

Erschienen in: Inflammation | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease that can lead to synovial inflammation, pannus formation, cartilage damage, bone destruction, and ultimate disability. Fibroblast-like synoviocytes (FLS) are involved in the pathogenetic mechanism of RA. Cdc37 (cell division cycle protein 37) is regarded as a molecular chaperone involved in various physiological processes such as cell cycle progression, cell proliferation, cell signal transduction, tumorigenesis, and progression. However, the precise role of Cdc37 in the pathogenesis of rheumatoid arthritis (RA) remains uncertain. In our study, we found that Cdc37 expression was upregulated in human rheumatoid synovia in contrast with the normal group. Interestingly, Cdc37 activated the ERK pathway to promote RA-FLS proliferation and migration in vitro. Ultimately, in vivo experiments revealed that silencing of Cdc37 alleviated ankle swelling and cartilage destruction and validated the ERK signaling pathways in vitro findings. Collectively, we demonstrate that Cdc37 promotes the proliferation and migration of RA-FLS by activation of ERK signaling pathways and finally aggravates the progression of RA. These data indicated that Cdc37 may be a novel target for the treatment of RA.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Niu, Y., Q. Dong, and R. Li. 2017. Matrine regulates Th1/Th2 cytokine responses in rheumatoid arthritis by attenuating the NF-kappaB signaling. Cell Biology International 41: 611–621.PubMedCrossRef Niu, Y., Q. Dong, and R. Li. 2017. Matrine regulates Th1/Th2 cytokine responses in rheumatoid arthritis by attenuating the NF-kappaB signaling. Cell Biology International 41: 611–621.PubMedCrossRef
2.
Zurück zum Zitat Agere, S.A., N. Akhtar, J.M. Watson, and S. Ahmed. 2017. RANTES/CCL5 induces collagen degradation by activating MMP-1 and MMP-13 expression in human rheumatoid arthritis synovial fibroblasts. Frontiers in Immunology 8: 1341.PubMedPubMedCentralCrossRef Agere, S.A., N. Akhtar, J.M. Watson, and S. Ahmed. 2017. RANTES/CCL5 induces collagen degradation by activating MMP-1 and MMP-13 expression in human rheumatoid arthritis synovial fibroblasts. Frontiers in Immunology 8: 1341.PubMedPubMedCentralCrossRef
3.
4.
Zurück zum Zitat Li, C.H., L.L. Xu, J.X. Zhao, L. Sun, Z.Q. Yao, X.L. Deng, R. Liu, L. Yang, R. Xing, and X.Y. Liu. 2016. CXCL16 upregulates RANKL expression in rheumatoid arthritis synovial fibroblasts through the JAK2/STAT3 and p38/MAPK signaling pathway. Inflammation Research 65: 193–202.PubMedCrossRef Li, C.H., L.L. Xu, J.X. Zhao, L. Sun, Z.Q. Yao, X.L. Deng, R. Liu, L. Yang, R. Xing, and X.Y. Liu. 2016. CXCL16 upregulates RANKL expression in rheumatoid arthritis synovial fibroblasts through the JAK2/STAT3 and p38/MAPK signaling pathway. Inflammation Research 65: 193–202.PubMedCrossRef
5.
Zurück zum Zitat Liu, Y., Y.F. Pan, Y.Q. Xue, L.K. Fang, X.H. Guo, X. Guo, M. Liu, B.Y. Mo, M.R. Yang, F. Liu, et al. 2018. uPAR promotes tumor-like biologic behaviors of fibroblast-like synoviocytes through PI3K/Akt signaling pathway in patients with rheumatoid arthritis. Cellular & Molecular Immunology 15: 171–181.CrossRef Liu, Y., Y.F. Pan, Y.Q. Xue, L.K. Fang, X.H. Guo, X. Guo, M. Liu, B.Y. Mo, M.R. Yang, F. Liu, et al. 2018. uPAR promotes tumor-like biologic behaviors of fibroblast-like synoviocytes through PI3K/Akt signaling pathway in patients with rheumatoid arthritis. Cellular & Molecular Immunology 15: 171–181.CrossRef
6.
Zurück zum Zitat Huber, L.C., O. Distler, I. Tarner, R.E. Gay, S. Gay, and T. Pap. 2006. Synovial fibroblasts: Key players in rheumatoid arthritis. Rheumatology (Oxford) 45: 669–675.PubMedCrossRef Huber, L.C., O. Distler, I. Tarner, R.E. Gay, S. Gay, and T. Pap. 2006. Synovial fibroblasts: Key players in rheumatoid arthritis. Rheumatology (Oxford) 45: 669–675.PubMedCrossRef
7.
Zurück zum Zitat Okamoto, H., K. Shidara, D. Hoshi, and N. Kamatani. 2007. Anti-arthritis effects of vitamin K(2) (menaquinone-4)–a new potential therapeutic strategy for rheumatoid arthritis. FEBS Journal 274: 4588–4594.PubMedCrossRef Okamoto, H., K. Shidara, D. Hoshi, and N. Kamatani. 2007. Anti-arthritis effects of vitamin K(2) (menaquinone-4)–a new potential therapeutic strategy for rheumatoid arthritis. FEBS Journal 274: 4588–4594.PubMedCrossRef
8.
Zurück zum Zitat Lee, H.S., S.J. Woo, H.W. Koh, S.O. Ka, L. Zhou, K.Y. Jang, H.S. Lim, H.O. Kim, S.I. Lee, and B.H. Park. 2014. Regulation of apoptosis and inflammatory responses by insulin-like growth factor binding protein 3 in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis. Arthritis & Rhematology 66: 863–873.CrossRef Lee, H.S., S.J. Woo, H.W. Koh, S.O. Ka, L. Zhou, K.Y. Jang, H.S. Lim, H.O. Kim, S.I. Lee, and B.H. Park. 2014. Regulation of apoptosis and inflammatory responses by insulin-like growth factor binding protein 3 in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis. Arthritis & Rhematology 66: 863–873.CrossRef
9.
Zurück zum Zitat Bartok, B., and G.S. Firestein. 2010. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunological Reviews 233: 233–255.PubMedPubMedCentralCrossRef Bartok, B., and G.S. Firestein. 2010. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunological Reviews 233: 233–255.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Nam, E.J., J.H. Kang, S. Sung, K.H. Sa, K.H. Kim, J.S. Seo, J.H. Kim, S.W. Han, I.S. Kim, and Y.M. Kang. 2013. A matrix metalloproteinase 1-cleavable composite peptide derived from transforming growth factor beta-inducible gene h3 potently inhibits collagen-induced arthritis. Arthritis and Rheumatism 65: 1753–1763.PubMedCrossRef Nam, E.J., J.H. Kang, S. Sung, K.H. Sa, K.H. Kim, J.S. Seo, J.H. Kim, S.W. Han, I.S. Kim, and Y.M. Kang. 2013. A matrix metalloproteinase 1-cleavable composite peptide derived from transforming growth factor beta-inducible gene h3 potently inhibits collagen-induced arthritis. Arthritis and Rheumatism 65: 1753–1763.PubMedCrossRef
11.
Zurück zum Zitat Verba, K.A., R.Y. Wang, A. Arakawa, Y. Liu, M. Shirouzu, S. Yokoyama, and D.A. Agard. 2016. Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase. Science 352: 1542–1547.PubMedPubMedCentralCrossRef Verba, K.A., R.Y. Wang, A. Arakawa, Y. Liu, M. Shirouzu, S. Yokoyama, and D.A. Agard. 2016. Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase. Science 352: 1542–1547.PubMedPubMedCentralCrossRef
12.
13.
Zurück zum Zitat Smith, J.R., P.A. Clarke, E. de Billy, and P. Workman. 2009. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 28: 157–169.PubMedCrossRef Smith, J.R., P.A. Clarke, E. de Billy, and P. Workman. 2009. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 28: 157–169.PubMedCrossRef
14.
Zurück zum Zitat Gray, P.J., Jr., M.A. Stevenson, and S.K. Calderwood. 2007. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Research 67: 11942–11950.PubMedCrossRef Gray, P.J., Jr., M.A. Stevenson, and S.K. Calderwood. 2007. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Research 67: 11942–11950.PubMedCrossRef
15.
Zurück zum Zitat El Hamidieh, A., N. Grammatikakis, and E. Patsavoudi. 2012. Cell surface Cdc37 participates in extracellular HSP90 mediated cancer cell invasion. PLoS ONE 7: e42722.PubMedPubMedCentralCrossRef El Hamidieh, A., N. Grammatikakis, and E. Patsavoudi. 2012. Cell surface Cdc37 participates in extracellular HSP90 mediated cancer cell invasion. PLoS ONE 7: e42722.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Wang, Z., W. Wei, C.K. Sun, M.S. Chua, and S. So. 2015. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth. Liver International 35: 1403–1415.PubMedCrossRef Wang, Z., W. Wei, C.K. Sun, M.S. Chua, and S. So. 2015. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth. Liver International 35: 1403–1415.PubMedCrossRef
17.
Zurück zum Zitat Schwarze, S.R., V.X. Fu, and D.F. Jarrard. 2003. Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Research 63: 4614–4619.PubMed Schwarze, S.R., V.X. Fu, and D.F. Jarrard. 2003. Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Research 63: 4614–4619.PubMed
18.
Zurück zum Zitat Ota, A., and Y. Wang. 2012. Cdc37/Hsp90 protein-mediated regulation of IRE1alpha protein activity in endoplasmic reticulum stress response and insulin synthesis in INS-1 cells. Journal of Biological Chemistry 287: 6266–6274.PubMedCrossRef Ota, A., and Y. Wang. 2012. Cdc37/Hsp90 protein-mediated regulation of IRE1alpha protein activity in endoplasmic reticulum stress response and insulin synthesis in INS-1 cells. Journal of Biological Chemistry 287: 6266–6274.PubMedCrossRef
19.
Zurück zum Zitat Liu, Y., S. Wang, D. Ding, Z. Yu, W. Sun, and Y. Wang. 2018. Up-regulation of Cdc37 contributes to Schwann cell proliferation and migration after sciatic nerve crush. Neurochemical Research 43: 1182–1190.PubMedCrossRef Liu, Y., S. Wang, D. Ding, Z. Yu, W. Sun, and Y. Wang. 2018. Up-regulation of Cdc37 contributes to Schwann cell proliferation and migration after sciatic nerve crush. Neurochemical Research 43: 1182–1190.PubMedCrossRef
20.
Zurück zum Zitat Zhang, H.G., Y. Wang, J.F. Xie, X. Liang, D. Liu, P. Yang, H.C. Hsu, R.B. Ray, and J.D. Mountz. 2001. Regulation of tumor necrosis factor alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis and Rheumatism 44: 1555–1567.PubMedCrossRef Zhang, H.G., Y. Wang, J.F. Xie, X. Liang, D. Liu, P. Yang, H.C. Hsu, R.B. Ray, and J.D. Mountz. 2001. Regulation of tumor necrosis factor alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis and Rheumatism 44: 1555–1567.PubMedCrossRef
21.
Zurück zum Zitat King, D., D. Yeomanson, and H.E. Bryant. 2015. PI3King the lock: Targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. Journal of Pediatric Hematology/oncology 37: 245–251.PubMedCrossRef King, D., D. Yeomanson, and H.E. Bryant. 2015. PI3King the lock: Targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. Journal of Pediatric Hematology/oncology 37: 245–251.PubMedCrossRef
22.
Zurück zum Zitat Chen, B.C., and W.W. Lin. 2001. PKC- and ERK-dependent activation of I kappa B kinase by lipopolysaccharide in macrophages: Enhancement by P2Y receptor-mediated CaMK activation. British Journal of Pharmacology 134: 1055–1065.PubMedPubMedCentralCrossRef Chen, B.C., and W.W. Lin. 2001. PKC- and ERK-dependent activation of I kappa B kinase by lipopolysaccharide in macrophages: Enhancement by P2Y receptor-mediated CaMK activation. British Journal of Pharmacology 134: 1055–1065.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Hsing, C.H., M.C. Lin, P.C. Choi, W.C. Huang, J.I. Kai, C.C. Tsai, Y.L. Cheng, C.Y. Hsieh, C.Y. Wang, Y.P. Chang, et al. 2011. Anesthetic propofol reduces endotoxic inflammation by inhibiting reactive oxygen species-regulated Akt/IKKbeta/NF-kappaB signaling. PLoS ONE 6: e17598.PubMedPubMedCentralCrossRef Hsing, C.H., M.C. Lin, P.C. Choi, W.C. Huang, J.I. Kai, C.C. Tsai, Y.L. Cheng, C.Y. Hsieh, C.Y. Wang, Y.P. Chang, et al. 2011. Anesthetic propofol reduces endotoxic inflammation by inhibiting reactive oxygen species-regulated Akt/IKKbeta/NF-kappaB signaling. PLoS ONE 6: e17598.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Li, D.W., X.T. Wang, B.C. Mu, D.Q. Dou, and T.G. Kang. 2021. Effects of hydroxysafflor yellow A on rats with collagen-induced arthritis. Biochemical and Biophysical Research Communications 570: 26–34.PubMedCrossRef Li, D.W., X.T. Wang, B.C. Mu, D.Q. Dou, and T.G. Kang. 2021. Effects of hydroxysafflor yellow A on rats with collagen-induced arthritis. Biochemical and Biophysical Research Communications 570: 26–34.PubMedCrossRef
25.
Zurück zum Zitat Yu, X., J. Zhou, F. Zhao, X. Liu, Y. Mao, L. Diao, C. Wen, and M. Liu. 2021. Tomatidine suppresses the destructive behaviors of fibroblast-like synoviocytes and ameliorates type II collagen-induced arthritis in rats. Frontiers in Pharmacology 12: 670707.PubMedPubMedCentralCrossRef Yu, X., J. Zhou, F. Zhao, X. Liu, Y. Mao, L. Diao, C. Wen, and M. Liu. 2021. Tomatidine suppresses the destructive behaviors of fibroblast-like synoviocytes and ameliorates type II collagen-induced arthritis in rats. Frontiers in Pharmacology 12: 670707.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Liu, C., A. Pan, X. Chen, J. Tu, X. Xia, and L. Sun. 2019. MiR-5571-3p and miR-135b-5p, derived from analyses of microRNA profile sequencing, correlate with increased disease risk and activity of rheumatoid arthritis. Clinical Rheumatology 38: 1753–1765.PubMedCrossRef Liu, C., A. Pan, X. Chen, J. Tu, X. Xia, and L. Sun. 2019. MiR-5571-3p and miR-135b-5p, derived from analyses of microRNA profile sequencing, correlate with increased disease risk and activity of rheumatoid arthritis. Clinical Rheumatology 38: 1753–1765.PubMedCrossRef
27.
Zurück zum Zitat Fan, W., Z. Xu, S. Liang, S. Zuo, C. Bian, X. Gao, Y. Qin, and J. Wu. 2021. MLL3 inhibits apoptosis of rheumatoid arthritis fibroblast-like synoviocytes and promotes secretion of inflammatory factors by activating CCL2 and the NF-kappaB pathway. Inflammation 44: 1803–1814.PubMedCrossRef Fan, W., Z. Xu, S. Liang, S. Zuo, C. Bian, X. Gao, Y. Qin, and J. Wu. 2021. MLL3 inhibits apoptosis of rheumatoid arthritis fibroblast-like synoviocytes and promotes secretion of inflammatory factors by activating CCL2 and the NF-kappaB pathway. Inflammation 44: 1803–1814.PubMedCrossRef
28.
Zurück zum Zitat Li, G., Y. Liu, F. Meng, Z. Xia, X. Wu, Y. Fang, C. Zhang, Y. Zhang, and D. Liu. 2019. LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/mTOR signalling pathway. Journal of Cellular and Molecular Medicine 23: 7116–7120.PubMedPubMedCentralCrossRef Li, G., Y. Liu, F. Meng, Z. Xia, X. Wu, Y. Fang, C. Zhang, Y. Zhang, and D. Liu. 2019. LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/mTOR signalling pathway. Journal of Cellular and Molecular Medicine 23: 7116–7120.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Philippe, L., G. Alsaleh, A. Pichot, E. Ostermann, G. Zuber, B. Frisch, J. Sibilia, S. Pfeffer, S. Bahram, D. Wachsmann, and P. Georgel. 2013. MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes. Annals of the Rheumatic Diseases 72: 1071–1079.PubMedCrossRef Philippe, L., G. Alsaleh, A. Pichot, E. Ostermann, G. Zuber, B. Frisch, J. Sibilia, S. Pfeffer, S. Bahram, D. Wachsmann, and P. Georgel. 2013. MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes. Annals of the Rheumatic Diseases 72: 1071–1079.PubMedCrossRef
30.
Zurück zum Zitat Zhang, T., H. Li, J. Shi, S. Li, M. Li, L. Zhang, L. Zheng, D. Zheng, F. Tang, X. Zhang, et al. 2016. p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis. Arthritis Research & Therapy 18: 271.CrossRef Zhang, T., H. Li, J. Shi, S. Li, M. Li, L. Zhang, L. Zheng, D. Zheng, F. Tang, X. Zhang, et al. 2016. p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis. Arthritis Research & Therapy 18: 271.CrossRef
31.
Zurück zum Zitat Liu, F.L., L.H. Lin, H.K. Sytwu, and D.M. Chang. 2010. GDF-5 is suppressed by IL-1beta and enhances TGF-beta3-mediated chondrogenic differentiation in human rheumatoid fibroblast-like synoviocytes. Experimental and Molecular Pathology 88: 163–170.PubMedCrossRef Liu, F.L., L.H. Lin, H.K. Sytwu, and D.M. Chang. 2010. GDF-5 is suppressed by IL-1beta and enhances TGF-beta3-mediated chondrogenic differentiation in human rheumatoid fibroblast-like synoviocytes. Experimental and Molecular Pathology 88: 163–170.PubMedCrossRef
32.
Zurück zum Zitat Qiu, H., S. Sun, X. Ma, C. Cui, G. Chen, Z. Liu, H. Li, and M. Liu M. 2018. Jatrorrhizine hydrochloride suppresses proliferation, migration, and secretion of synoviocytes in vitro and ameliorates rat models of rheumatoid arthritis in vivo. Internation Journal of Molecular Sciences 19. Qiu, H., S. Sun, X. Ma, C. Cui, G. Chen, Z. Liu, H. Li, and M. Liu M. 2018. Jatrorrhizine hydrochloride suppresses proliferation, migration, and secretion of synoviocytes in vitro and ameliorates rat models of rheumatoid arthritis in vivo. Internation Journal of Molecular Sciences 19.
33.
Zurück zum Zitat Lee, J.W., J. Lee, S.H. Um, and E.Y. Moon. 2017. Synovial cell death is regulated by TNF-alpha-induced expression of B-cell activating factor through an ERK-dependent increase in hypoxia-inducible factor-1alpha. Cell Death & Disease 8: e2727.CrossRef Lee, J.W., J. Lee, S.H. Um, and E.Y. Moon. 2017. Synovial cell death is regulated by TNF-alpha-induced expression of B-cell activating factor through an ERK-dependent increase in hypoxia-inducible factor-1alpha. Cell Death & Disease 8: e2727.CrossRef
34.
Zurück zum Zitat Huang, C.C., C.H. Chiou, S.C. Liu, S.L. Hu, C.M. Su, C.H. Tsai, and C.H. Tang. 2019. Melatonin attenuates TNF-alpha and IL-1beta expression in synovial fibroblasts and diminishes cartilage degradation: Implications for the treatment of rheumatoid arthritis. Journal of Pineal Research 66: e12560.PubMedCrossRef Huang, C.C., C.H. Chiou, S.C. Liu, S.L. Hu, C.M. Su, C.H. Tsai, and C.H. Tang. 2019. Melatonin attenuates TNF-alpha and IL-1beta expression in synovial fibroblasts and diminishes cartilage degradation: Implications for the treatment of rheumatoid arthritis. Journal of Pineal Research 66: e12560.PubMedCrossRef
35.
Zurück zum Zitat Pinto, L.G., J. Talbot, R.S. Peres, R.F. Franca, S.H. Ferreira, B. Ryffel, J.C. Aves-Filho, F. Figueiredo, T.M. Cunha, and F.Q. Cunha. 2015. Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1beta production. Arthritis Research & Therapy 17: 235.CrossRef Pinto, L.G., J. Talbot, R.S. Peres, R.F. Franca, S.H. Ferreira, B. Ryffel, J.C. Aves-Filho, F. Figueiredo, T.M. Cunha, and F.Q. Cunha. 2015. Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1beta production. Arthritis Research & Therapy 17: 235.CrossRef
36.
Zurück zum Zitat Sparks, J.A. 2019. Rheumatoid Arthritis. Annals of Intern Medicine 170: ITC1-ITC16. Sparks, J.A. 2019. Rheumatoid Arthritis. Annals of Intern Medicine 170: ITC1-ITC16.
37.
Zurück zum Zitat Krasselt, M., and C. Baerwald. 2019. Celecoxib for the treatment of musculoskeletal arthritis. Expert Opinion on Pharmacotherapy 20: 1689–1702.PubMedCrossRef Krasselt, M., and C. Baerwald. 2019. Celecoxib for the treatment of musculoskeletal arthritis. Expert Opinion on Pharmacotherapy 20: 1689–1702.PubMedCrossRef
38.
Zurück zum Zitat Wang, W., H. Zhou, and L. Liu. 2018. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. European Journal of Medicinal Chemistry 158: 502–516.PubMedCrossRef Wang, W., H. Zhou, and L. Liu. 2018. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. European Journal of Medicinal Chemistry 158: 502–516.PubMedCrossRef
39.
Zurück zum Zitat Lin, Y.J., M. Anzaghe, and S. Schulke. 2020. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 9. Lin, Y.J., M. Anzaghe, and S. Schulke. 2020. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 9.
40.
Zurück zum Zitat Alfaro-Lara, R., H.F. Espinosa-Ortega, and C.A. Arce-Salinas. 2019. Precis study group apbtDoIMHCSdP: Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin (Engl Ed) 15: 133–139.PubMedCrossRef Alfaro-Lara, R., H.F. Espinosa-Ortega, and C.A. Arce-Salinas. 2019. Precis study group apbtDoIMHCSdP: Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin (Engl Ed) 15: 133–139.PubMedCrossRef
41.
Zurück zum Zitat Aletaha, D., and J.S. Smolen. 2018. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA 320: 1360–1372.PubMedCrossRef Aletaha, D., and J.S. Smolen. 2018. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA 320: 1360–1372.PubMedCrossRef
42.
Zurück zum Zitat Pappas, D.A., G. St John, C.J. Etzel, S. Fiore, T. Blachley, T. Kimura, R. Punekar, K. Emeanuru, J. Choi, S. Boklage, and J.M. Kremer. 2021. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: Results from a large US registry study. Annals of the Rheumatic Diseases 80: 96–102.PubMedCrossRef Pappas, D.A., G. St John, C.J. Etzel, S. Fiore, T. Blachley, T. Kimura, R. Punekar, K. Emeanuru, J. Choi, S. Boklage, and J.M. Kremer. 2021. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: Results from a large US registry study. Annals of the Rheumatic Diseases 80: 96–102.PubMedCrossRef
43.
Zurück zum Zitat Nygaard, G., and G.S. Firestein. 2020. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nature Reviews Rheumatology 16: 316–333.PubMedPubMedCentralCrossRef Nygaard, G., and G.S. Firestein. 2020. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nature Reviews Rheumatology 16: 316–333.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Lee, C.W., Y.C. Kwon, Y. Lee, M.Y. Park, and K.M. Choe. 2019. cdc37 is essential for JNK pathway activation and wound closure in Drosophila. Molecular Biology of the Cell 30: 2651–2658.PubMedPubMedCentralCrossRef Lee, C.W., Y.C. Kwon, Y. Lee, M.Y. Park, and K.M. Choe. 2019. cdc37 is essential for JNK pathway activation and wound closure in Drosophila. Molecular Biology of the Cell 30: 2651–2658.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Eguchi, T., T.L. Prince, M.T. Tran, C. Sogawa, B.J. Lang, and S.K. Calderwood. 2019. MZF1 and SCAND1 reciprocally regulate CDC37 gene expression in prostate cancer. Cancers (Basel) 11. Eguchi, T., T.L. Prince, M.T. Tran, C. Sogawa, B.J. Lang, and S.K. Calderwood. 2019. MZF1 and SCAND1 reciprocally regulate CDC37 gene expression in prostate cancer. Cancers (Basel) 11.
46.
Zurück zum Zitat Calvisi, D.F., R.M. Pascale, and F. Feo. 2007. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Reviews on Recent Clinical Trials 2: 217–236.PubMedCrossRef Calvisi, D.F., R.M. Pascale, and F. Feo. 2007. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Reviews on Recent Clinical Trials 2: 217–236.PubMedCrossRef
47.
Zurück zum Zitat Umar, S., K. Palasiewicz, K. Van Raemdonck, M.V. Volin, B. Romay, I. Ahmad, C. Tetali, N. Sweiss, M.A. Amin, R.K. Zomorrodi, and S. Shahrara. 2021. CCL25 and CCR9 is a unique pathway that potentiates pannus formation by remodeling RA macrophages into mature osteoclasts. European Journal of Immunology 51: 903–914.PubMedPubMedCentralCrossRef Umar, S., K. Palasiewicz, K. Van Raemdonck, M.V. Volin, B. Romay, I. Ahmad, C. Tetali, N. Sweiss, M.A. Amin, R.K. Zomorrodi, and S. Shahrara. 2021. CCL25 and CCR9 is a unique pathway that potentiates pannus formation by remodeling RA macrophages into mature osteoclasts. European Journal of Immunology 51: 903–914.PubMedPubMedCentralCrossRef
Metadaten
Titel
Inhibition of Cdc37 Ameliorates Arthritis in Collagen-Induced Arthritis Rats by Inhibiting Synoviocyte Proliferation and Migration Through the ERK Pathway
verfasst von
Weiwei Sun
Xingxing Mao
Weijie Wu
Yunyi Nan
Chunxiang Xu
Youhua Wang
Hua Xu
Publikationsdatum
15.03.2023
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 3/2023
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-023-01789-3

Weitere Artikel der Ausgabe 3/2023

Inflammation 3/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.